Precision Cancer Therapy in Rare Cancers

Recruiting now · Phase 2

Conditions studied: Rare Malignant Neoplasm

In brief

Some rare cancers are hard-to-treat and patients have a poor prognosis. It is known that some of these patients have targetable molecular alterations, and some benefit from targeted drugs. However in many cases these drugs are not approved for the rare cancers. In this study the aim is to do advanced molecular diagnostics to identify possible targets for therapy, and to treat accordingly.

Key facts

Study ID

NCT06119789

Run by

Oslo University Hospital

People needed

96

Starts

2025-03-20

Expected to finish

2036-08-01

Last updated by the study team

2025-03-26

Who can join

Age: 16 and older, up to 99. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• ECOG 0-2,
• identified biomarker,
• reasonable biochemistry

You may not qualify if…

• ECOG 3-5
• serious other diseases

Where it is running

• Oslo University Hospital — Oslo, Norway (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.